Merck Emend Not “Full Replacement” For I.V. Anti-Emetics – GSK, Roche
Executive Summary
Merck's Emend should not be covered under Medicare Part B for treatment of chemotherapy-induced emesis because it is not a "full replacement" for currently covered products, GlaxoSmithKline and Roche argue in comments to CMS